{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:20:50Z","timestamp":1790734850366,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.japh.2023.12.020","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T10:43:20Z","timestamp":1703501000000},"page":"457-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis"],"prefix":"10.1016","volume":"64","author":[{"given":"Mariah","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6219-5722","authenticated-orcid":false,"given":"Kristina","family":"Vizcaino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Ewing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"St. Ville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2023.12.020_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J.\u00a0Am. Coll. Cardiol"},{"issue":"11","key":"10.1016\/j.japh.2023.12.020_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2023.12.020_bib3","series-title":"Apixaban [package insert]","year":"2021"},{"key":"10.1016\/j.japh.2023.12.020_bib4","series-title":"Warfarin [package insert]","year":"2012"},{"issue":"7","key":"10.1016\/j.japh.2023.12.020_bib5","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J.\u00a0Am. Soc. Nephrol"},{"issue":"5","key":"10.1016\/j.japh.2023.12.020_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J\u00a0Clin Pharm"},{"issue":"2","key":"10.1016\/j.japh.2023.12.020_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/rth2.12083","article-title":"Safety and effectiveness of apixaban compared to warfarin in dialysis patients","volume":"2","author":"Reed","year":"2018","journal-title":"Res. Pract. Thromb. Haemost"},{"issue":"11","key":"10.1016\/j.japh.2023.12.020_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"23","key":"10.1016\/j.japh.2023.12.020_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.japh.2023.12.020_bib10","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123004326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123004326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:00Z","timestamp":1761544380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123004326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1544319123004326"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.12.020","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}